REMINET: A European, Multicenter, Phase II/III Randomized Double-Blind, Placebo-Controlled Study Evaluating Lanreotide As Maintenance Therapy after First-Line Treatment in Patients with Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors Abstract #1763

Introduction: Patients (pts) with metastatic or locally advanced, non-resectable, grade 1 or 2 Well-differentiated duodeno-pancreatic (WDDP) NETs are treated following European guidelines. Pts with aggressive disease, i.e. progressive and/or symptomatic metastases and/or with significant hepatic invasion (> 30-50%), and/or bone metastases, anti-tumour therapy should receive systemic combination of chemotherapy once disease control is obtained.
Aim(s): The aim is to stop chemotherapy until progression. REMINET is an academic randomized, double-blind, placebo-controlled, phase II/III study designed to evaluate whether lanreotide (LAN) as maintenance treatment after L1 therapy.
Materials and methods: Main eligibility criteria: Adults pts with a metastatic (synchronous or metachronous) or locally advanced, non-resectable, grade 1 or 2 WDDP NETs and documented control disease after L1 therapy at least 4 weeks prior to randomization.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment – Chemotherapy, medical treatment - others
Presenting Author: Côme Lepage

To read results and conclusion, please login ...

Further abstracts you may be interested in

#992 Phase 1 and Phase 2 Clinical Trials Investigating Targets Against the Molecular Hallmarks of Gastroenteropancreatic Neuroendocrine Tumors
Introduction: Recently there have been many advances in the diagnosis and treatment of gastroenteropancreatic neuroendocrine tumors (GEP NETs), accompanied by significant improvements in our understanding of GEP NET biology. A number of well-established or novel molecular hallmarks are involved in GEP NET tumorigenesis and may help in identifying potential diagnostic or therapeutic targets.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Others
Presenting Author: Dr Gianluca Tamagno
#1107 The Chicken Chorioallantoic Membrane Assay as a Preclinical Model for the Research of Rare Gastrointenstinal Neuroendocrine Tumours
Introduction: Preclinical trials of cancer therapeutics require both in vitro and in vivo evaluations. For neuroendocrine tumours (NET) studies are limited to cell lines, thus xenograft models are needed for screening and evaluation of anti-cancer drugs. The chick chorioallantoic membrane (CAM) assay is a well-established model system to investigate tumour growth, angiogenesis and metastasis.
Conference: 12th Annual ENETS Conference (2015)
Category: ...none of the below
Presenting Author: PhD Nassim Ghaffari Tabrizi-Wizsy
Authors: Passegger C, Kump P, Haybäck J, Lipp R, ...
#2163 Peptide Receptor Radionuclide Therapy in Patients with Metastatic Neuroendocrine Carcinomas: Case Series
Introduction: High-grade neuroendocrine carcinomas (NECs) possess inevitable tendencies to metastasise and hold poor prospects of survival. Patients with neuroendocrine tumours who progress after medical management can be treated with peptide receptor radionuclide therapy (PRRT), on the proviso that there is positive uptake on 68Ga-DOTATATE PET/CT imaging. Despite this, a proportion of patients who exhibit positive imaging respond poorly to therapy. Management of NECs is currently limited; evidence for treating NECs with PRRT is scarce.
Conference: 15th Annual ENETS conference (2018)
Category: Case reports
Presenting Author: Shamus Butt
Authors: Butt S, Evans J, Sharma R, ...
#300 Association Between Time to Disease Progression Endpoints and Overall Survival in Patients with Neuroendocrine Tumors
Introduction: While the association between time to disease progression (TDP) and overall survival (OS) has been examined in a variety of cancers, it has not been assessed in trials of neuroendocrine tumors (NETs).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Thomas E Delea
Authors: Delea T E, Rotter J, Wang X, ...
#151 Rationale for combining mTOR with other targeted agents in the treatment of neuroendocrine tumors
Introduction: Advanced neuroendocrine tumors (NETs) are aggressive and incurable with standard treatment. Many cellular targets are being evaluated in this patient population, including mammalian target of rapamycin (mTOR), a kinase that is the central regulator of several signaling pathways related to cell growth, angiogenesis, and bioenergetics. Because mTOR serves as a neoplastic switch activated by many cancer-related mutations, mTOR inhibition may have broad efficacy across tumor types, including NETs. Somatostatin analogs (SSAs) have long been used to treat carcinoid symptoms in NET patients. The SSA octreotide long-acting release (LAR) demonstrated significant antitumor effects against advanced midgut NETs in the phase III PROMID study.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Kjell Öberg
Authors: Öberg K, Yao J C, ...